Coverage
-
May 05, 2020
Amgen Inc. may have staved off generic competition for its injectable anti-cancer drug Kyprolis for another seven years, after a Delaware federal judge refused to declare a trio of patents tied to the drug invalid.
2 other articles on this case.
View all »